Enrollment complete in 2 Phase 2 trials testing hepatitis B treatment
Enrollment is complete in two Phase 2 clinical trials testing Ausperbio’s AHB-137 in people with chronic hepatitis B, the company said. That “positions us…
Marisa Wexler, MS, Senior Science Writer—
Articles by Marisa Wexler
Program improves hepatitis C treatment access for new moms
A simple shift in where new mothers receive care is helping the fight against hepatitis C. By bringing infectious disease specialists to a mother’s…
FDA OKs clinical trials to test cell therapy for chronic hepatitis B
The U.S. Food and Drug Administration (FDA) has given Lion TCR the green light to start Phase 1b/2 clinical trials testing LioCyx-M004, the clinical-stage…
Alcohol consumption disrupts protein that controls liver fat: Study
Exposure to excessive alcohol disrupts the activity of a protein that plays a key role in keeping liver fat healthy, a study found. Researchers said…
Gene-editing approach may one day cure chronic hepatitis B: Study
A gene-editing therapy designed to specifically inactivate a hidden genetic blueprint of the hepatitis B virus (HBV) — the cause of hepatitis B —…
New trial data show saroglitazar works to ease liver damage in PBC
One year of treatment with saroglitazar, Zydus Therapeutics’ experimental oral candidate, outperformed a placebo at normalizing markers of liver injury in people with…
Age at Kasai, spleen issues key to biliary atresia outcomes
Babies who had standard Kasai surgery when they were more than 60 days old or had spleen malformations were more likely to have poor outcomes…
Canada clears fast fingerstick test for hepatitis C
A one-hour point-of-care test for hepatitis C has been cleared for use in Canada, which could help accelerate diagnosis and monitor how people with…
FDA gives conditional approval to Wegovy for some liver patients
The U.S. Food and Drug Administration (FDA) has conditionally approved Novo Nordisk’s Wegovy (semaglutide) to treat certain people with metabolic dysfunction-associated steatohepatitis (MASH), a…
NorUDCA becomes first MASLD therapy approved in India
India’s Central Drugs Standard Control Organization has approved the oral therapy nor-ursodeoxycholic acid (NorUDCA) for people with metabolic dysfunction-associated steatotic liver disease (MASLD), a form…